Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 233-244

  Minelli, R ^a   Occhipinti, S ^a   Gigliotti, C L ^b   Barrera, G ^a   Gasco, P ^c   Conti, L ^a   Chiocchetti, A ^b   Zara, G P ^a   Fantozzi, R ^a   Giovarelli, M ^a   Dianzani, U ^b   Dianzani, C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NANOVECTOR S R L   (Italy)

Author keywords

cholesteryl butyrate; clonogenic assay; solid lipid nanoparticles; tumour growth in vivo

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; CHOLESTEROL BUTYRATE; PROTEIN KINASE B; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IMAGING; G2 PHASE CELL CYCLE CHECKPOINT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LD 50; LUNG METASTASIS; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING; ZETA POTENTIAL;

CHOLESTERYL BUTYRATE; CLONOGENIC ASSAY; SOLID LIPID NANOPARTICLES; TUMOUR GROWTH IN VIVO;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL ESTERS; COLONIC NEOPLASMS; FEMALE; HUMANS; LIPIDS; MALE; MICE; MICE, SCID; NANOPARTICLES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883225189     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12255     Document Type: Article

References (37)

1. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA, (2004). The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23: 8571-8580.
2. Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A, (2008). Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 13: 230-254.
3. Davis ME, Chen ZG, Shin DM, (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
4. Delzenne N, Cherbut C, Neyrinck A, (2003). Prebiotics: actual and potential effect in inflammatory and malignant colonic disease. Curr Opin Clin Nutr Metab Care 6: 581-586.
5. Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, et al. (2006). Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 148: 648-656.
6. Dianzani C, Minelli R, Mesturini R, Chiocchetti A, Barrera G, Boscolo S, et al. (2010). B7h triggering inhibits umbelical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells. J Immunol 185: 3970-3979.
7. Gasco MR, (2004). Solid lipid nanospheres suitable to a fast internalization into cells. EP 1133286, (24/11/2004)-U.S. 6.685.960 (3/02/2004).
8. Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, Decaestecker C, (2006). Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol 211: 30-40.
9. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M, (2002). Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94: 3127-3134.
10. Iwahshi T, Okochi E, Ono K, Sugawara I, Tsuruo T, Mori S, (1991). Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anticancer Res 11: 1309-1312.
11. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH, (2004). Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 25: 241-248.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
13. Kobayashi H, Tan EM, Fleming SE, (2003). Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells independently of p53 status. Nutr Cancer 46: 202-211.
14. Kwiatkowska A, Kijewska M, Lipko M, Hibner U, Kaminska B, (2011). Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813: 655-667.
15. Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, et al. (2010). Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 58: 2935-2942.
16. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, et al. (2010). Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 53: 6337-6354.
17. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, et al. (2007). Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28: 572-583.
18. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ, (2006). Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78.
19. Matsumura Y, Kataoka K, (2009). Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 100: 572-579.
20. Matsuoka T, Yashiro M, Nishioka N, Hirakawa K, Olden K, Roberts JD, (2012). PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma. Br J Cancer 106: 1535-1542.
21. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Minelli R, Serpe L, Pettazzoni P, Minero V, Barrera G, Gigliotti C, et al. (2012). Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br J Pharmacol 166: 587-601.
23. Minucci S, Pelicci PG, (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
24. Mosier DE, Stell KL, Gulizia RJ, Torbett BE, Gilmore GL, (1993). Homozygous scid/scid; beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med 177: 191-194.
25. Pellizzaro C, Coradini D, Morel S, Ugazio E, Gasco MR, Daidone MG, (1999). Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res 19: 3921-3926.
26. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. (2002). Akt proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205.
27. Salomone B, Ponti R, Gasco MR, Ugazio E, Quaglino P, Osella-Abate S, et al. (2001). In vitro effects of cholesteryl butyrate solid lipd nanospheres as a butyric acid prodrug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis 18: 663-673.
28. Serpe L, Laurora S, Pizzimenti S, Ugazio E, Ponti R, Canaparo R, et al. (2004). Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 15: 525-536.
29. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S, (2007). Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424-1432.
30. Singh R, Lillard JW Jr, (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86: 215-223.
31. Stein U, Walther W, Shoemaker RH, (1996). Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88: 1383-1392.
32. Thomsen M, Galvani S, Canivet C, Kamar N, Böler T, (2008). Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology 246: 18-23.
33. Wang F, Arun P, Friedman J, Chen Z, Van Waes C, (2009). Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9: 389-395.
34. Wilson AJ, Chueh AC, Tögel L, Corner GA, Ahmed N, Goel S, et al. (2010). Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70: 609-620.
35. Wollowski I, Rechkemmer G, Pool-Zobel BL, (2001). Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73: 451S-455S.
36. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY, (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59: 491-504.
37. Wu C, Huang J, (2007). PI3 kinase-Akt-mTOR pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282: 3571-3583.